Loading clinical trials...
Loading clinical trials...
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Laboratory Classroom Study to Evaluate the Safety and Efficacy of PRC-063 Compared to Placebo in Children (6-12 Years of Age) With ADHD
Conditions
Interventions
PRC-063 oral capsules
Placebo oral capsules
Locations
6
United States
AVIDA Inc.
Newport Beach, California, United States
Meridien Research Inc.
Bradenton, Florida, United States
Meridien Research Inc.
Maitland, Florida, United States
Qps Mra Llc
Miami, Florida, United States
Center for Psychiatry and Behavioral Medicine
Las Vegas, Nevada, United States
Bayou City Research
Houston, Texas, United States
Start Date
May 1, 2017
Primary Completion Date
August 19, 2017
Completion Date
December 19, 2017
Last Updated
November 5, 2019
NCT07478458
NCT07465081
NCT07314333
NCT07189442
NCT06711224
NCT06221358
Lead Sponsor
Purdue Pharma, Canada
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions